Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
J Biol Chem ; 287(30): 25530-40, 2012 Jul 20.
Artigo em Inglês | MEDLINE | ID: mdl-22669972

RESUMO

Fas is a member of the death receptor family. Stimulation of Fas leads to induction of apoptotic signals, such as caspase 8 activation, as well as "non-apoptotic" cellular responses, notably NF-κB activation. Convincing experimental data have identified NF-κB as a critical promoter of cancer development, creating a solid rationale for the development of antitumor therapy that suppresses NF-κB activity. On the other hand, compelling data have also shown that NF-κB activity enhances tumor cell sensitivity to apoptosis and senescence. Furthermore, although stimulation of Fas activates NF-κB, the function of NF-κB in the Fas-mediated apoptosis pathway remains largely undefined. In this study, we observed that deficiency of either Fas or FasL resulted in significantly increased incidence of 3-methylcholanthrene-induced spontaneous sarcoma development in mice. Furthermore, Fas-deficient mice also exhibited significantly greater incidence of azoxymethane and dextran sodium sulfate-induced colon carcinoma. In addition, human colorectal cancer patients with high Fas protein in their tumor cells had a longer time before recurrence occurred. Engagement of Fas with FasL triggered NF-κB activation. Interestingly, canonical NF-κB was found to directly bind to the FAS promoter. Blocking canonical NF-κB activation diminished Fas expression, whereas blocking alternate NF-κB increased Fas expression in human carcinoma cells. Moreover, although canonical NF-κB protected mouse embryo fibroblast (MEF) cells from TNFα-induced apoptosis, knocking out p65 diminished Fas expression in MEF cells, resulting in inhibition of FasL-induced caspase 8 activation and apoptosis. In contrast, knocking out p52 increased Fas expression in MEF cells. Our observations suggest that canonical NF-κB is a Fas transcription activator and alternate NF-κB is a Fas transcription repressor, and Fas functions as a suppressor of spontaneous sarcoma and colon carcinoma.


Assuntos
Apoptose , Neoplasias do Colo/metabolismo , Subunidade p52 de NF-kappa B/metabolismo , Neoplasias Experimentais/metabolismo , Sarcoma/metabolismo , Fator de Transcrição RelA/metabolismo , Proteínas Supressoras de Tumor/metabolismo , Receptor fas/metabolismo , Animais , Caspase 8/genética , Caspase 8/metabolismo , Neoplasias do Colo/induzido quimicamente , Neoplasias do Colo/genética , Embrião de Mamíferos/metabolismo , Embrião de Mamíferos/patologia , Proteína Ligante Fas/genética , Proteína Ligante Fas/metabolismo , Fibroblastos/metabolismo , Fibroblastos/patologia , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Regulação Neoplásica da Expressão Gênica/genética , Humanos , Metilcolantreno/toxicidade , Camundongos , Camundongos Knockout , Subunidade p52 de NF-kappa B/genética , Neoplasias Experimentais/induzido quimicamente , Neoplasias Experimentais/genética , Regiões Promotoras Genéticas/genética , Sarcoma/induzido quimicamente , Sarcoma/genética , Sarcoma/patologia , Fator de Transcrição RelA/genética , Proteínas Supressoras de Tumor/genética , Receptor fas/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA